Intensive exercise does not prevent the loss of fat-free mass following SGLT2 inhibitor treatment. However, it enhances the reduction of abdominal fat, potentially leading to more significant improvements in hyperglycemia and chronic inflammation compared to DAPA alone in T2DM patients. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.